Up next are two clinical trials, a phase-two clinical trial for GP1681 in the area of Covid-19 and a separate clinical that will determine how it works with CAR-T patients. It’s shaping up to be a busy year for Pittsburgh-based CytoAgents, an early stage pharmaceutical company based in Pittsburgh whose drug candidate. Read more >>
After stopping to help someone on the freeway, and getting hit himself, Jamie Harrell spent about two months in…
read moreOn Wednesday, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation…
read moreDaktari Diagnostics, a company focused on making “Anywhere. Care.™” a reality with its portable and ultrasensitive immunoassay-based CarePlatform™, today…
read moreRegroup Mass Notification, the industry-leading provider of mass communication solutions, today announced that it has received a nomination for…
read moreRepublican Senator Rand Paul has introduced a bill that would allow Americans to dip into their 401(k) savings to…
read moreThis revolutionary technology was developed at the Massachusetts Institute of Technology and the device was created at the Cambridge-based…
read moreRising usage of atypical antipsychotics, omega‐3 fatty acids, antidepressants, glutamateric neurotransmission modulators, erythropoietin, COX‐2 inhibitors and N‐acetylcysteine have anti‐apoptotic…
read moreThe eye wear technology company, eSight, has launched the third generation of its hands-free glasses that provide instant sight…
read moreTeresa Harper shows off her eSight glasses at the Lions Industries for the Blind. Read more >>
read moreToday, executives from Xylyx Bio announced the launch of VIVIQ Skin Health, a consumer brand that leverages proprietary ECM…
read more